Argen X SE ADR

ARGXNASDAQ · USD
960.04USD0.00 (-2.17%)
529

Argen X SE ADR (ARGX) Implied Volatility Current

ARGX's 30 day implied volatility is 40.73%, with an IV Rank of 69.05%. This is an average IV Rank versus the past year, meaning Argen X SE ADR options are fairly priced and currently offer no clear edge to buyers or sellers. ARGX's 30 day historical volatility sits at 51.46%, which means implied volatility is running 10.73 points below historical volatility, as of Nov 13, 2026.

Read more

Tracking ARGX implied volatility helps you spot when Argen X SE ADR options are historically cheap or expensive, and where the best trades are hiding. When ARGX IV rises, premiums increase and sellers get more attractive pricing, and when it drops, buyers find cheaper contracts. Use our scanner to monitor ARGX implied volatility current levels in real time and filter for high probability trades.

Implied volatility is derived from option prices and represents the annualized expected move of a stock. Tracking ARGX IV rank helps you see whether ARGX's implied volatility is historically high or low, since IV rank compares today's reading against the past year's range. A high rank signals relatively expensive premiums and tends to favor sellers, a low rank signals relatively cheap premiums and tends to favor buyers.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

Implied Volatility

IV Rank
69.05%IV Rank
Moderate

IV is slightly elevated. Premiums are richer, leaning toward sellers.

Implied Volatility (30d)40.73%

IV Rank69.05%

Historical Volatility (30d)51.46%

IV Minus HV-10.73%

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →